Rituximab Combined with Steroid and Tacrolimus Treats Proliferative Glomerulonephritis with Monoclonal IgG Deposits: A Case Report and Review of the Literature

Title:Rituximab Combined with Steroid and Tacrolimus Treats Proliferative Glomerulonephritis with Monoclonal IgG Deposits: A Case Report and Review of the Literature

Volume: 31

Author(s): Di Liu, Ming Xia, Chang Wang, Xuejing Zhu, Guochun Chen and Hong Liu*

Affiliation:

• Hunan Key Laboratory of Kidney Disease and Blood Purification, Department of Nephrology, The Second Xiangya Hospital of Central South University, No. 139 Renmin Middle Rd, Changsha, 410011, Hunan, China

Abstract: Introduction: Due to the confounding heterogeneity, the therapeutic strategy for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) remains to be defined.

Case Representation: We report a 38-year-old man with recurrent swelling of the eyelids and lower limbs, undergoing rituximab combined with steroid and tacrolimus treatment, who achieved an improved renal outcome. Underlying solid malignant tumours were excluded from the diagnosis.

Discussion: We treated patients with rituximab along with steroids and tacrolimus. Improvements in proteinuria and renal function were observed. We also reviewed the current literature to assess the efficacy of rituximab in the treatment of PGNMID.

Conclusion: However, a larger pool of patients and a longer follow-up period are required to establish the role of rituximab and steroids in the treatment of PGNMID.

Cite this article as:

Liu Di, Xia Ming, Wang Chang, Zhu Xuejing, Chen Guochun and Liu Hong*, Rituximab Combined with Steroid and Tacrolimus Treats Proliferative Glomerulonephritis with Monoclonal IgG Deposits: A Case Report and Review of the Literature, Current Medicinal Chemistry 2024; 31 () . https://dx.doi.org/10.2174/0109298673272183240108093135